Bicara Therapeutics Inc. ...

11.83
-1.43 (-10.78%)
At close: Apr 03, 2025, 3:59 PM
11.69
-1.18%
Pre-market: Apr 04, 2025, 04:26 AM EDT

Company Description

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors.

Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

The company was incorporated in 2018 and is based in Boston, Massachusetts.

Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc. Common Stock logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 55
CEO Claire Mazumdar Clemon M.B.A., Ph.D.

Contact Details

Address:
116 Huntington Avenue
Boston, Massachusetts
United States
Website https://www.bicara.com

Stock Details

Ticker Symbol BCAX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0002023658
CUSIP Number 055477103
ISIN Number US0554771032
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Claire Mazumdar Clemon M.B.A., Ph.D. Chief Executive Officer & Director
Ivan Hyep M.B.A. Chief Financial Officer
Lara S. Meisner J.D. Chief Legal Officer & Corporate Secretary
Ryan Cohlhepp Pharm.D. President, Chief Operating Officer & Director
Angela Windt Vice President & Head of Regulatory Affairs
Dr. David Raben M.D. Chief Medical Officer
Dr. Jeltje Schulten M.B.A., M.D. Senior Vice President of Clinical & Medical Affairs
Jean-Paul Rodrique Senior Vice President & Global Head of Quality Assurance
Rachel Salazar SVice President of R&D Strategy and Operations
Sathish Hasige Ph.D. Senior Vice President and Head of Technical Operations & Supply Chain

Latest SEC Filings

Date Type Title
Mar 28, 2025 S-8 Filing
Mar 27, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Mar 18, 2025 4 Filing
Mar 03, 2025 SCHEDULE 13G Filing
Feb 12, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 13, 2025 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Sep 26, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Sep 26, 2024 SC 13G Statement of acquisition of beneficial ownership b...